DDInter1141 DDInter1658
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Megestrol acetate {u} (Compound) resembles {v} (Compound) Methyltestosterone
Megestrol acetate {u} (Compound) binds {v} (Gene) PGR
Megestrol acetate {u} (Compound) palliates {v} (Disease) breast cancer
Megestrol acetate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Megestrol acetate (Compound) resembles Dydrogesterone (Compound)
Megestrol acetate (Compound) resembles Methyltestosterone (Compound)
Megestrol acetate (Compound) binds PGR (Gene)
Megestrol acetate (Compound) palliates breast cancer (Disease)
Megestrol acetate (Compound) is included by Progesterone Congeners (Pharmacologic Class)